Ben Venue Laboratories, Inc. (d/b/a Bedford Laboratories)

I'll research this company before writing the profile.

Ben Venue Laboratories, Inc. (d/b/a Bedford Laboratories) — Sterile-injectable contract manufacturer and generic injectables business headquartered at 300 Northfield Road, Bedford, Ohio. Founded in 1938, the company was acquired by Boehringer Ingelheim Corporation on December 1, 1997 and operated as a wholly owned subsidiary of the privately held German parent (C.H. Boehringer Sohn AG & Co. KG). Ben Venue Laboratories, Inc. was itself incorporated in Delaware. The company reported roughly 1,100–1,180 employees at its Bedford site in its final years; a 2014 acquirer disclosure put Bedford's revenue near $19 million with $22 million in operating costs. (Employee figures come from company/industry profiles and closure reporting; no audited revenue figure is public.)

Operations. Ben Venue was a contract manufacturer of sterile parenterals for pharmaceutical and biotech clients, offering aseptic filling, lyophilization (freeze-drying), vacuum drying, terminal sterilization, packaging/labeling, formulation and process development, stability testing, and analytical/ microbiological QC. Its Bedford Laboratories business sold generic sterile injectables in the U.S., concentrated in acute-care hospitals and oncology; reporting at the time of its 2014 sale described it as holding the third-largest U.S. generic injectable portfolio, with 84 marketed products and a 27-product pipeline. Its largest customer relationship was with the National Cancer Institute, dating to 1967.

Patent-litigation posture. Ben Venue appears once in the database, and only as a defendant (0 plaintiff suits). That profile is consistent with an operating company being sued, not an NPE: this was ordinary Hatch-Waxman brand-versus-generic litigation, not an assertion campaign. The single case was filed in the District of Delaware — a common venue for ANDA suits given the defendant's Delaware incorporation, and not a plaintiff-friendly NPE district.

Notable case. Helsinn Healthcare S.A. v. Ben Venue Laboratories, Inc. (d/b/a Bedford Laboratories), filed September 25, 2013 (D. Del.), arose from Ben Venue's ANDA No. 205048 seeking approval of generic palonosetron hydrochloride injection, a version of Helsinn's Aloxi®. Helsinn asserted Orange Book patents on liquid palonosetron formulations; the Delaware action was consolidated with parallel ANDA suits against other generics makers that produced the litigation later considered by the Supreme Court in Helsinn v. Teva (2019) on the AIA on-sale bar.

Corporate aftermath. After FDA cGMP findings, a November 2011 voluntary manufacturing halt, and a January 2013 consent decree, Ben Venue ceased production in December 2013 and laid off roughly 1,100 staff. Hikma Pharmaceuticals agreed in May 2014 to acquire Bedford's assets and the Bedford, Ohio site for up to $300 million; Hikma later sold the manufacturing buildings to Xellia Pharmaceuticals in 2015. Ben Venue as an operating entity effectively no longer exists.